The PI3Kβ isoform is an important lipid kinase that regulates the PI3K signalling pathway and the survival of PTEN-deficient tumour cells, so PI3Kβ inhibitors have a role in PTEN-deficient cancers and are expected to improve clinical efficacy through drug combination.84 Here, PIK3CG is linked to neoplasm.